Life Science Labs Signal Shifting Strategies Amid New Economic Pressures, According to Survey of 550+ Researchers
While the first wave of the survey was fielded prior to the announcement of new tariff policies, the second wave offers a timely comparison as labs began adjusting to anticipated policy changes under the Trump administration and broader macroeconomic pressures, including inflation, tightened research budgets, and supply chain strain.
Click here to download the Lab Budgets & Funding Survey
Key Survey Findings Include:
Funding confidence is declining, with only 57% of labs reporting confidence in securing 2025 funding—down from 66% in the first wave.
Financial strain is hitting North American labs harder than those in Europe: 46% report new funding challenges (vs. 21% in Europe), and over half are considering personnel cuts, compared to just 28% in Europe.
42% of labs cite new concerns about securing funding through year-end, signaling heightened financial risk across the sector.
Cost-saving strategies are accelerating, including resource sharing, supplier renegotiations, outsourcing, and delayed equipment purchases.
These findings reflect shifting institutional priorities and underscore the growing need for timely, market-aligned planning as labs face increased constraints and financial pressure.
"By fielding this survey before and after key policy announcements, we're able to offer a real-time snapshot of how labs are adjusting to economic volatility," said Richa Singh, VP, Market Insights at BioInformatics. "As tariff policies begin to reshape lab planning, companies need focused, evidence-backed insights to align their strategies. This data helps commercial teams track funding sentiment, adapt messaging, and make confident, evidence-based decisions—especially in a market where priorities can change within weeks."
About Beyond the Bench
Beyond the Bench is a free monthly intelligence series created by BioInformatics to help life science and diagnostics companies understand how customer sentiment and commercial priorities are shifting—particularly during times of uncertainty and industry disruption. Powered by the Science Advisory Board, BioInformatics' proprietary network of over 55,000 life science professionals, each report delivers survey-based insights on market trends, strategic shifts, and buyer behavior.
The series was launched to provide a clear, unbiased view into the evolving challenges facing researchers and decision-makers—giving commercial teams actionable guidance to align strategy, messaging, and resource planning with what matters most to their customers.
Access & Get Involved:
Download the Lab Budgets & Funding Survey
Sign up to receive monthly Beyond the Bench reports
Join the Science Advisory Board — qualify to participate in surveys, earn rewards, and shape the future of scientific research.
About BioInformatics
BioInformatics, part of the Science and Medicine Group, is a leading market research and advisory firm serving the life science and diagnostic industries. The company delivers custom and syndicated research powered by a proprietary global panel of more than 55,000 professionals.
https://www.scienceandmedicinegroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/life-science-labs-signal-shifting-strategies-amid-new-economic-pressures-according-to-survey-of-550-researchers-302481395.html
SOURCE BioInformatics Inc.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Intel's Frankfurt-listed shares rise 3.6% after report US could take stake in chipmaker
LONDON (Reuters) -Intel's Frankfurt-listed shares rose 3.6% on Friday, a day after Bloomberg News reported the Trump administration is in talks with the struggling chipmaker to have the U.S. government potentially take a stake in the company. Intel's U.S. shares surged more than 7% in regular trading Thursday and then another 2.6% after the bell. Intel on Thursday declined to comment on the report. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNBC
28 minutes ago
- CNBC
Oil maintains gains ahead of Trump-Putin summit
Oil prices nudged higher on Friday to fresh one-week highs after U.S. President Donald Trump warned of "consequences" if Russia blocked a Ukraine peace deal, injecting concerns about supply. Sentiment was also boosted by strong economic data out of Japan, which is among the largest global crude importers. Brent crude futures gained 16 cents, or 0.2%, to $67.00 a barrel by (0017 GMT). U.S. West Texas Intermediate crude futures were up 14 cents, also 0.2%, to $64.10. All eyes are on Friday's meeting of Trump and Russian leader Vladimir Putin in Alaska where a ceasefire in the Ukraine war is at the top of the agenda. A continued conflict between Russia and Ukraine supports oil markets by limiting the supply of Russian oil. Trump, however, also said he believes Russia is prepared to end the war in Ukraine. Fresh Japanese government data released on Friday showed the economy expanded an annualized 1.0% in the April-June quarter, compared with a median market forecast for a 0.4% increase. The rise in gross domestic product (GDP) translated into a quarterly increase of 0.3%, compared with a median estimate of a 0.1% increase. Strong economic activity typically spurs oil consumption. Prospects of higher-for-longer U.S. interest rates, however, kept oil prices from rising further. Higher-than-expected inflation data and weak jobs numbers out of the U.S. raised concerns that the Federal Reserve would keep interest rates high, usually a dampener of oil consumption.


CNBC
an hour ago
- CNBC
India is looking to buy Russian oil at a discount
Ahead of the Trump / Putin meeting in Alaska - CNBC's Dan Murphy and Sri Jegarajah discuss the implications of possible punitive U.S. sanctions on Russian oil, and those who purchase it - including India.